Viridian Therapeutics, Inc.
Description
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
About
CEO
Mr. Stephen F. Mahoney J.D., MBA
Employees
94
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNCM
Address
221 Crescent Street, Waltham, MA 02453, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 10, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Feb 25, 2025 | — | — | — | — |
| Nov 12, 2024 | -1.06 | -1.15 | -0.09 | 8.49% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 12 |
| Average estimate | — | -1.04 | — | -4.18 |
| Low estimate | — | -1.30 | — | -5.34 |
| High estimate | — | -0.84 | — | -3.17 |
| Last year EPS | — | -0.79 | — | -3.85 |
[stock_revenue_estimate]
Growth estimates
Current qtr
22.650%
Next qtr. (Mar 2025)
-31.960%
Current year
24.900%
Next year (Dec 2025)
-5.760%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 314,000 | 1.77M | 2.96M | 1.05M | 4.46M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 159.77M | 100.89M | 56.89M | 28.30M | 34.79M |
| Selling general and admin | 95.00M | 35.18M | 25.81M | 13.27M | 11.65M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -254.45M | -134.30M | -79.73M | -40.52M | -41.98M |
| Non operating interest income | |||||
| Income | 18.56M | 4.92M | 318,000 | 173,000 | 941,000 |
| Expense | 1.85M | 486,000 | 3,000 | 508,000 | 835,000 |
| Other income expense | — | — | — | -69.86M | — |
| Pretax income | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M |
| Tax provision | — | — | — | — | — |
| Net income | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M |
| Basic EPS | -5.31 | -4.05 | -6.66 | -31.13 | -20.10 |
| Diluted EPS | -5.31 | -4.05 | -6.66 | -31.13 | -20.10 |
| Basic average shares | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M |
| Diluted average shares | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M |
| EBITDA | -235.37M | -129.13M | -79.29M | -40.11M | -40.75M |
| Net income from continuing op. | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 490.42M | 435.09M | 203.71M | 131.26M | 30.26M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M |
| Other short term investments | 374.54M | 268.97M | 154.67M | 81.74M | 2.00M |
| Accounts receivable | — | — | — | — | 108,000 |
| Other receivables | 102,000 | 102,000 | 451,000 | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 2.75M | 1.97M | 2.89M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 9.01M | 6.52M | 2.75M | 1.97M | 2.89M |
| Non current assets | |||||
| Properties | 2.82M | 2.77M | 2.46M | 2.99M | 2.51M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 906,000 | 1.06M | 627,000 | 502,000 | 623,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 670,000 | 1.11M | 749,000 | 741,000 | 741,000 |
| Accumulated depreciation | -1.05M | -2.00M | -1.78M | -3.44M | -3.35M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 604,000 | 982,000 | 1.49M | 1.71M | — |
| Total liabilities | 48.40M | 40.03M | 15.99M | 11.22M | 14.51M |
| Current liabilities | |||||
| Accounts payable | 2.24M | 14.23M | 2.33M | 670,000 | 1.10M |
| Accrued expenses | 12.65M | 13.34M | 6.75M | 7.19M | 4.43M |
| Short term debt | 843,000 | 613,000 | 520,000 | 455,000 | 3.98M |
| Deferred revenue | 288,000 | 288,000 | 289,000 | 301,000 | 66,000 |
| Tax payable | — | — | — | — | — |
| Pensions | 10.51M | 4.77M | 3.65M | 1.96M | 508,000 |
| Other current liabilities | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 |
| Non current liabilities | |||||
| Long term debt | 20.21M | 4.65M | — | — | 4.33M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 989,000 | 1.17M | 1.21M | 43,000 | — |
| Shareholders equity | |||||
| Common stock | 540,000 | 414,000 | 239,000 | 42,000 | 23,000 |
| Retained earnings | -725.91M | -488.17M | -358.30M | -278.89M | -168.17M |
| Other shareholders equity | 338,000 | -390,000 | -157,000 | -8,000 | — |
| Total shareholders equity | 442.02M | 395.06M | 187.72M | 120.04M | 15.75M |
| Additional paid in capital | 960.54M | 741.07M | 412.10M | 218.09M | 183.90M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.70M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
| Depreciation | 522,000 | 255,000 | 120,000 | 239,000 | 288,000 | 281,000 | 308,000 | 189,000 | 184,000 | 144,000 | 148,000 | 144,289 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 67.17M | 19.77M | 14.47M | 3.65M | 3.97M | 3.68M | 2.41M | 2.11M | 3.02M | 4.30M | — | 7,955 |
| Other Non-Cash Items | 6.60M | 264,000 | 7.49M | 72.57M | 340,000 | 376,000 | 94,000 | 93,000 | 132,000 | 953,000 | 1.69M | 2.49M |
| Accounts Receivable | — | 349,000 | -451,000 | — | -84,000 | 1.43M | -1.44M | -130,000 | 694,000 | -94,000 | 202,000 | -369,579 |
| Accounts Payable | -12.04M | 11.52M | 1.66M | -426,000 | 525,000 | -335,000 | -101,000 | 2.03M | 633,000 | 383,000 | -280,000 | -1.29M |
| Other Assets & Liabilities | -288,000 | -288,000 | 636,000 | — | — | — | — | 123,000 | -8,000 | 178,000 | -187,000 | 166,392 |
| Operating Cash Flow | -175.77M | -98.01M | -55.50M | -34.69M | -36.83M | -27.27M | -25.24M | -8.26M | -6.68M | -2.03M | -590,000 | -4.47M |
| Investing Activities | ||||||||||||
| Capital Expenditures | -898,000 | -797,000 | -259,000 | -42,000 | -84,000 | -445,000 | -246,000 | -3,000 | -123,000 | -266,000 | -5,000 | -87,613 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | 29.37M | — | — | 1.28M | — | — | — | — | — |
| Purchase of Investments | -407.88M | -223.26M | -188.43M | -81.81M | -32.69M | -62.46M | — | — | — | — | — | — |
| Sale of Investments | 314.53M | 108.94M | 114.40M | 2.00M | 61.00M | 33.00M | — | — | — | — | — | — |
| Investing Cash Flow | -94.25M | -115.13M | -74.29M | -50.48M | 28.23M | -29.91M | 1.03M | -3,000 | -95,000 | -274,000 | 6,000 | -119,433 |
| Financing Activities | ||||||||||||
| Long-Term Debt Issuance | 15.00M | 5.00M | — | 1.73M | — | — | 10.00M | — | — | 795,000 | 12.57M | 6.64M |
| Long-Term Debt Payments | — | — | — | -10.29M | -2.33M | — | -4.67M | -84,000 | -76,000 | -42,000 | -10.52M | -59,427 |
| Other Financing Charges | -12.32M | -22.51M | -8.28M | -6.22M | -77,000 | -3.04M | -1.85M | — | 50,000 | — | -500,422 | -50,000 |
| Financing Cash Flow | 203.95M | 318.36M | 122.92M | 101.31M | 70,000 | 41.49M | 52.05M | -257,000 | 12.71M | 7.40M | 758,578 | 5.81M |
| Other Cash Details | ||||||||||||
| End Cash Position | 102.83M | 155.58M | 42.30M | 45.90M | 24.85M | 32.61M | 47.44M | 3.34M | 10.83M | 5.12M | 209,000 | 112,534 |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 886,000 | 293,000 | — | 267,000 | 511,000 | 489,000 | 446,000 | 2,000 | 6,000 | 1,000 | 1.21M | — |
| Free Cash Flow | -185.07M | -94.64M | -54.92M | -29.82M | -36.14M | -27.29M | -28.41M | -7.23M | -7.02M | -2.48M | -1.17M | -6.33M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 2,243,124 | 43.16M | 2.83% |
| Fidelity Select Portfolios - Health Care | Nov 30, 2024 | 2,000,000 | 38.48M | 2.52% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,750,675 | 33.68M | 2.21% |
| Fidelity Advisor Biotechnology Fund | Nov 30, 2024 | 1,533,376 | 29.50M | 1.94% |
| Fidelity Advisor Health Care Fund | Nov 30, 2024 | 1,200,000 | 23.09M | 1.51% |
| Fidelity Select Portfolios - Biotechnology | Nov 30, 2024 | 1,053,728 | 20.27M | 1.33% |
| Fidelity Small Cap Growth Fund | Oct 31, 2024 | 1,054,475 | 20.29M | 1.33% |
| AB Cap Fd.-AB Small Cap Growth Port | Dec 31, 2024 | 1,011,150 | 19.45M | 1.28% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 989,696 | 19.04M | 1.25% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 947,291 | 18.23M | 1.20% |
Article
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 527,750 shares of the company's common stock to 15 new employees (the “Inducem.
Feb 6, 2025
Article
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and catalysts for 2025. “After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney, Viridian's President and CEO. “We believe that the positive and better-than-expect.
Jan 8, 2025
Article
Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade)
Company reported positive phase 3 THRIVE-2 study results using veligrotug in treating chronic thyroid eye disease patients, positioning it to file a BLA in the 2nd half 2025. The company is developing VRDN-003, an improved subcutaneous version of veligrotug for TED patients, with phase 3 REVEAL-1 and REVEAL-2 topline data expected in early 2026. Promising pipeline candidates include FcRn inhibitors VRDN-006 and bispecific VRDN-008, targeting IgG-mediated autoimmune disorders with potentially superior efficacy.
Dec 19, 2024
